Leukemia Exploration and Prevention Grant Program (LEAP) supports investigators and teams studying leukemia development and preventive approaches for people with RUNX1 familial platelet disorder.
Funder: American Cancer Society
Due Dates (Anticipated): June 2027 (Application deadline)
Funding Amounts: Research Scholar: up to $946,000 | Team: up to $1.892 million, each over four years including allowable indirect costs
Summary: Supports investigator-initiated research to enable cancer interception and prevention for people with RUNX1 familial platelet disorder.
Key Information: Applicants must be full-time independent investigators at eligible US institutions and may apply for only one funding mechanism.
The Leukemia Exploration and Prevention Grant Program (LEAP) is a partnership between the American Cancer Society (ACS) and the RUNX1 Research Program. It supports independent investigators and interdisciplinary teams developing biological insights and translational approaches toward preventing or intercepting hematologic malignancies in people with RUNX1 familial platelet disorder (RUNX1-FPD).
Projects must address one of two focus areas. The first investigates mechanisms underlying successive leukemogenic steps, from germline RUNX1-mutated hematopoietic stem/progenitor cells acquiring harmful somatic mutations through clonal expansion and overt leukemia, considering both cell-autonomous and cell-nonautonomous factors. The second supports translational research identifying, developing, or validating actionable targets, pathways, biomarkers, or intervention strategies. Preclinical and clinical efforts may be supported when positioned to translate biological insights into practical preventive or interceptive approaches.